How to Monitor Disease in the Health Management of Patients with Chronic Pulmonary Combination
In the health management of patients with chronic pulmonary cancer combined, disease surveillance is essential to help patients to keep abreast of changes, adjust treatment programmes, improve quality of life and anticipate.
Periodic review
1. Lung function examination:
Pulmonary functional examination is an important indicator for assessing the severity of slow lung resistance. The respiratory function of the patient can be seen by measuring parameters such as the activity of the lung, the amount of air excretion, and the volume of air excretion in the first second.
• It is recommended that patients undergo a lung function check every 3 to 6 months in order to detect changes in lung function in a timely manner. If there is a significant reduction in lung function, the doctor may adjust the treatment programme based on the results of the examination, such as increasing the dose or type of bronchial expansion agent.
2. Chest CT:
The chest CT is an important means of monitoring the progress of lung cancer. It clearly shows the size, location, morphology and transfer of lung tumours.
During general chemotherapy, patients generally undergo a blood-script examination at each course of treatment, and during the immunization maintenance phase, a low-dose CT examination of the chest is generally carried out for 3-6 months. If there are signs of tumour growth, new nostrils or transfer, doctors can adjust treatment programmes, such as surgery, treatment, chemotherapy or targeting.
3. Oncology marker detection:
Oncological markers are substances produced by tumour cells or by the reaction of the organism to tumour cells, which can be detected in blood. Common tumour markers are the carcinogen antigens (CEA), neuronspecific ethanol enzymes (NSE), cytochrome 19 (CYFRA21-1), etc.
• Patients should be regularly tested for signs of tumour, usually every 1 to 3 months. If the number of tumor markers rises, it may indicate that lung cancer is progressing, and the doctor can make a comprehensive determination in conjunction with other examinations.
Blood testing:
Blood tests provide information on patients’ blood patterns, liver and kidney functions, electrolytics, etc. Long-term drug use may be required for patients with chronic pulmonary cancer, and blood tests can monitor the side effects of drugs.
• It is recommended that the patient undergo a blood test every 1 – 2 months. If heterogeneic abnormalities, damage to liver and kidney function or Electrolytic disorders are detected, the doctor can adjust the medication in a timely manner.
5. Other inspections:
• Depending on the patient’s circumstances, doctors may also recommend other examinations, such as EKGs, heart ultrasound, bone scans, etc. These examinations help doctors to understand the heart function of the patient, whether there is bone transfer, etc.
Self-monitoring
Symptoms observation:
Patients should closely follow their own symptoms, such as cough, cough, breathing difficulties, chest pain, blood. If symptoms are aggravated or new symptoms occur, they should be referred to the hospital in a timely manner.
• For example, the increase in the frequency and extent of coughing may be an expression of slow lung intensification or progress in lung cancer; the change of cough colour from white to yellow or green may indicate infection; the increase in respiratory difficulties, which may be caused by a reduction in lung function or by a lung cancer violation of the aerobics; and chest pains, engravings, which may be the manifestation of lung cancer to the pleural or vascular effects.
2. Body state perception:
• Patients should be aware of changes in their physical strength, appetite and weight. The disease may be a sign of worsening if it is felt that it is clearly weak, has reduced physical strength, has diminished appetite and has continued to reduce body weight.
In addition, patients should be concerned about their sleep quality, emotional change, etc. Insomnia, anxiety, depression etc. should also be reported to the doctor in time for appropriate treatment.
3. Daily activity monitoring:
• Patients can record their daily activities, such as walking distance, stairs, etc. If they are found to have decreased mobility, this may be a sign of reduced lung function or poor physical condition.
At the same time, patients can monitor their haematological saturation using simple equipment such as pulsed blood oxy. If oxygen saturation is below normal range, timely medical treatment should be provided.
In general, patients with chronic pulmonary conjunctivation are required to perform disease surveillance, to combine periodic review and self-monitoring, to detect changes in the condition in a timely manner, to adjust treatment programmes, to improve the quality of life and to anticipate. At the same time, patients must actively cooperate with doctors, maintain good mental attitudes and living habits, and provide a solid basis for combating the disease.
